New Zealand markets close in 1 hour 13 minutes

Guangdong Taienkang Pharmaceutical Co., Ltd. (301263.SZ)

Shenzhen - Shenzhen Delayed price. Currency in CNY
Add to watchlist
13.93-0.11 (-0.78%)
As of 11:32AM CST. Market open.
Currency in CNY

Valuation measures4

Market cap (intra-day) 5.97B
Enterprise value 5.51B
Trailing P/E 37.95
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.74
Price/book (mrq)3.25
Enterprise value/revenue 7.29
Enterprise value/EBITDA 29.94

Trading information

Stock price history

Beta (5Y monthly) -0.18
52-week change 3-29.41%
S&P500 52-week change 326.14%
52-week high 323.99
52-week low 311.65
50-day moving average 314.07
200-day moving average 316.32

Share statistics

Avg vol (3-month) 33.26M
Avg vol (10-day) 32.44M
Shares outstanding 5425.5M
Implied shares outstanding 6428.71M
Float 8230.53M
% held by insiders 152.38%
% held by institutions 110.30%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.3
Forward annual dividend yield 42.14%
Trailing annual dividend rate 30.30
Trailing annual dividend yield 32.14%
5-year average dividend yield 4N/A
Payout ratio 4189.19%
Dividend date 3N/A
Ex-dividend date 423 May 2024
Last split factor 21.8:1
Last split date 329 May 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 20.33%
Operating margin (ttm)28.68%

Management effectiveness

Return on assets (ttm)4.94%
Return on equity (ttm)7.58%

Income statement

Revenue (ttm)756.11M
Revenue per share (ttm)1.82
Quarterly revenue growth (yoy)-2.40%
Gross profit (ttm)N/A
EBITDA 215.09M
Net income avi to common (ttm)153.68M
Diluted EPS (ttm)0.37
Quarterly earnings growth (yoy)-12.50%

Balance sheet

Total cash (mrq)675.8M
Total cash per share (mrq)1.6
Total debt (mrq)211.58M
Total debt/equity (mrq)11.30%
Current ratio (mrq)4.32
Book value per share (mrq)4.33

Cash flow statement

Operating cash flow (ttm)16.55M
Levered free cash flow (ttm)-128.3M